PMID: 8892457Sep 1, 1996

Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience

International Journal of Radiation Oncology, Biology, Physics
K E DusenberyW G Woods

Abstract

To report the outcome of autologous bone marrow transplantation for patients with acute myeloid leukemia (AML) in first or greater complete remission (CR) treated by autologous bone marrow transplantation using two different preparatory regimens. Between September 1986 and August 1993, 75 patients with AML ranging in age from 6 months to 58 years underwent autologous bone marrow transplantation using previously harvested and frozen unpurged (n = 6) or 4-hydroperoxycyclophosphamide purged marrows (n = 69). Patients were in first CR (n = 44) or beyond first CR (n = 31). The preparative regimen consisted of 120 mg/kg of cyclophosphamide (CY) and 1320 cGy total body irradiation (TBI) in eight fractions over 4 days (CY/TBI) in 29 patients; and 16 mg/kg of Busulfan (BU) and 200 mg/kg of CY (BU/CY) in 46 patients. Thirty-five of these 75 patients (18 CY/TBI and 17 BU/CY) were part of a randomized trial comparing the two preparative regimens. At 2 years, overall survival and disease-free survival (DFS) were 49% [95% confidence interval (C.I.) 37-61%] and 43% (95% C.I. 32-55%), respectively. Patients in first CR had a significantly better outcome than patients beyond first CR with an estimated 2-year DFS of 59% (95% C.I. 44-74%) vs. 21%...Continue Reading

References

Jan 1, 1992·Bone Marrow Transplantation·M KörblingA Kessinger
Jan 1, 1992·International Journal of Clinical & Laboratory Research·V RizzoliC Carlo-Stella
Jun 1, 1980·International Journal of Radiation Oncology, Biology, Physics·F M KhanT H Kim
Jan 1, 1995·International Journal of Radiation Oncology, Biology, Physics·B Shank

Citations

Oct 4, 2005·International Journal of Radiation Oncology, Biology, Physics·Sagus SampathJeffrey Wong
Mar 7, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·T E Wheldon, A J Barrett
Nov 7, 2002·International Journal of Radiation Oncology, Biology, Physics·Martin BorgAnthony C Thomas
Nov 11, 2005·Medical Physics·Susanta K HuiJames S Welsh
Oct 2, 1998·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·F LohrM Wannenmacher
Feb 13, 2003·Pediatric Clinics of North America·Ulrike Reiss, Ellen Bolotin
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·John Mascarenhas, Ronald Hoffman
Jul 31, 1999·Annals of Internal Medicine·S FaderlH M Kantarjian
Feb 14, 2004·European Journal of Haematology·Nora-Athina ViniouGerassimos A Pangalis
Jun 30, 1998·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·T G Wendt
Jul 29, 1998·Cancer Investigation·B Shank

Related Concepts

Acute Disease
n-Butane-1,3-di(methylsulfonate)
Cyclophosphamide, (S)-Isomer
Graft Survival
Leukemia, Monocytic, Chronic
Relapse
Transplantation, Autologous
Confounding Factors (Epidemiology)
Survival Analysis
Bone Marrow Cell Transplantation

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.